Enzo Biochem, Inc.

NYSE:ENZ Stock Report

Market Cap: US$39.8m

Enzo Biochem Management

Management criteria checks 1/4

Enzo Biochem's CEO is Kara Cannon, appointed in Sep 2023, has a tenure of 1.25 years. total yearly compensation is $999.35K, comprised of 37.7% salary and 62.3% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $210.11K. The average tenure of the management team and the board of directors is 1.3 years and 1 years respectively.

Key information

Kara Cannon

Chief executive officer

US$999.4k

Total compensation

CEO salary percentage37.7%
CEO tenure1.3yrs
CEO ownership0.5%
Management average tenure1.3yrs
Board average tenure1yrs

Recent management updates

Recent updates

Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk

Dec 18
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk

Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?

Nov 19
Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?

Enzo Biochem: Is This Time Finally Different?

Jul 17

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

May 18
Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Jan 03
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Dec 12

Enzo Biochem appoints Patricia Eckert as interim CFO

Oct 20

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Oct 14

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Oct 04
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Jun 27

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

May 03
Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Dec 17
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Aug 24
Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Mar 01
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Feb 03
Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08
If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13
Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

CEO Compensation Analysis

How has Kara Cannon's remuneration changed compared to Enzo Biochem's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-US$7m

Jul 31 2024US$999kUS$376k

-US$10m

Apr 30 2024n/an/a

-US$18m

Jan 31 2024n/an/a

-US$23m

Oct 31 2023n/an/a

-US$25m

Jul 31 2023US$1mUS$299k

-US$25m

Apr 30 2023n/an/a

-US$27m

Jan 31 2023n/an/a

-US$24m

Oct 31 2022n/an/a

-US$23m

Jul 31 2022US$769kUS$270k

-US$20m

Apr 30 2022n/an/a

-US$7m

Jan 31 2022n/an/a

US$300k

Oct 31 2021n/an/a

US$5m

Jul 31 2021US$426kUS$265k

US$8m

Apr 30 2021n/an/a

US$1m

Jan 31 2021n/an/a

-US$11m

Oct 31 2020n/an/a

-US$21m

Jul 31 2020US$371kUS$220k

-US$29m

Apr 30 2020n/an/a

-US$31m

Jan 31 2020n/an/a

US$2m

Oct 31 2019n/an/a

US$822k

Jul 31 2019US$379kUS$220k

US$2m

Apr 30 2019n/an/a

US$2m

Jan 31 2019n/an/a

-US$23m

Oct 31 2018n/an/a

-US$16m

Jul 31 2018US$342kUS$198k

-US$10m

Compensation vs Market: Kara's total compensation ($USD999.35K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Kara's compensation has been consistent with company performance over the past year.

CEO

Kara Cannon (55 yo)

1.3yrs

Tenure

US$999,352

Compensation

Ms. Kara Cannon serves as Chief Executive Officer and Director at Enzo Biochem, Inc. from January 31, 2024. She served as Interim CEO at Enzo Biochem, Inc. since September 5, 2023 until January 31, 2024 an...

Leadership Team

NamePositionTenureCompensationOwnership
Kara Cannon
CEO & Director1.3yrsUS$999.35k0.53%
$ 210.1k
Patricia Eckert
Chief Financial Officer2.1yrsUS$490.04k0.054%
$ 21.6k
Brian Fisher
General Counsel & Secretaryless than a yearno datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: ENZ's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Kara Cannon
CEO & Directorless than a yearUS$999.35k0.53%
$ 210.1k
Steven Pully
Independent Chairperson of the Board1.2yrsUS$204.03k0.034%
$ 13.5k
Jonathan Couchman
Independent Directorless than a yearno data0.53%
$ 211.4k
Bradley Radoff
Independent Director2.9yrsUS$218.75k8.25%
$ 3.3m

1.0yrs

Average Tenure

54.5yo

Average Age

Experienced Board: ENZ's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/10/31
Annual Earnings2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley BerningCraig-Hallum Capital Group LLC
Reni BenjaminRodman & Renshaw, LLC
Jack WallaceSidoti & Company, LLC